Navigation Links
Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
Date:7/11/2012

AUSTIN, Texas, July 11, 2012 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the second quarter of 2012 on Monday, July 30, 2012. A press release announcing the results is scheduled for release after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the second quarter and six months ended June 30, 2012 on July 30, 2012, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the About Us section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Announces Agreement to Acquire GenturaDx
2. Luminex Corporation Reports First Quarter 2012 Results
3. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
4. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
5. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
6. Celladon Corporation Receives Notice of Allowance from European Patent Office
7. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
8. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
9. Centene Corporation Selected for Ohio Medicaid Contract
10. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
11. Ivera Medical Corporation Denies Patent Infringement Allegations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, a ... for hospitalized patients and their practitioners, announced today that ... funding. Velano will use the proceeds from this financing, ... completed in January 2015, to support the development and ... and pediatric populations. Philadelphia ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 ... ... pelvic organ prolapse with the latest techniques and the most minimally invasive approaches. ... pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to the ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
Breaking Medicine News(10 mins):